Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Engimmune Therapeutics
Engimmune Therapeutics is a biopharmaceutical company founded in 2021 that develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumor cancers.…
Engimmune Therapeutics
Engimmune Therapeutics is a biopharmaceutical company founded in 2021 that develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumor cancers.…
TL;DR
Founded: 2021
Headquarters: Basel, Switzerland
Focus: AI-guided protein engineering of off-the-shelf soluble TCR therapeutics for solid tumors
Lead financing: Seed round May 2022 (CHF 15.5M)
Stage: Preclinical (lead asset)
Company Overview
Problem Domain
Solid tumor oncology and immune-mediated diseases
Founded
2021
Industry
Biotechnology
Funding Track Record
CHF 15.5 million
Seed round co-led by Pureos Bioventures and Novo Holdings
Investor Signal
“Investors include Novo Holdings and Pureos Bioventures”